| Company Name: |
TargetMol |
| Tel: |
400-821-0310 15002144251 |
| Email: |
xuexiang.shao@tsbiochem.com |
|
| | Benzamide, 2-[[2-[[4-(aminosulfonyl)phenyl]amino]-5-bromo-4-pyrimidinyl]amino]-6-fluoro- Basic information |
| | Benzamide, 2-[[2-[[4-(aminosulfonyl)phenyl]amino]-5-bromo-4-pyrimidinyl]amino]-6-fluoro- Chemical Properties |
| Boiling point | 679.4±65.0 °C(Predicted) | | density | 1.743±0.06 g/cm3(Predicted) | | pka | 9.75±0.12(Predicted) |
| | Benzamide, 2-[[2-[[4-(aminosulfonyl)phenyl]amino]-5-bromo-4-pyrimidinyl]amino]-6-fluoro- Usage And Synthesis |
| Uses | TMX-3013 is a CDKs inhibitor capable of inhibiting the activity of CDK1, CDK2, CDK4, CDK5, and CDK6, with IC50 values of 0.9 nM, <0.5 nM, 24.5 nM, 0.5 nM, and 15.6 nM, respectively. TMX-3013 can be utilized for synthesizing PROTACs that feature a polyethylene glycol (PEG) linker arm and Thalidomide (HY-14658) as the CRBN-recruiting arm[1]. | | IC 50 | CDK1: 0.9 nM (IC50); CDK2: <0.5 nM (IC50); CDK4: 24.5 nM (IC50); CDK5: 0.5 nM (IC50); CDK6: 15.6 nM (IC50) | | References | [1] Teng M, et al. Development of CDK2 and CDK5 dual degrader TMX‐2172[J]. Angewandte Chemie, 2020, 132(33): 13969-13974. DOI:10.1002/anie.202004087 |
| | Benzamide, 2-[[2-[[4-(aminosulfonyl)phenyl]amino]-5-bromo-4-pyrimidinyl]amino]-6-fluoro- Preparation Products And Raw materials |
|